SCH772984

09/22/2021 - "Thus, this study defined transcriptome signatures of SCH772984 action in vitro and in vivo, an agent that has the potential to improve sepsis outcome."
09/22/2021 - "Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models."
09/22/2021 - "SCH772984 treatment improved survival in the LPS-induced lethal endotoxemia and cecal ligation and puncture (CLP) mouse models of sepsis, and reduced plasma levels of Ccl2/Mcp1. "

01/13/2022 - "In this study, the efficacy of combined PI3K/mTOR (BEZ235) and ERK inhibition (SCH772984) was investigated in four human ovarian cancer cell lines, grown as monolayer and three-dimensional cell aggregates. "

11/09/2023 - "This study intends to investigate the signaling pathways involved in LPS-induced hypoglycemia and potential efficacy of ERK inhibitor SCH772984. "
11/09/2023 - "SCH772984 ameliorates lipopolysaccharide induced hypoglycemia in mice through reversing MEK/ERK/Foxo1 mediated gluconeogenesis suppression."

01/01/2022 - "Finally, the cancer promotion phenomenon caused by BTN3A3 knockdown can be improved by using ERK1/2 inhibitor SCH772984. "
01/01/2021 - "In addition, SCH772984 exerted a strong effect on inhibiting tumor growth. "
01/01/2018 - "The dual mechanism inhibitor SCH772984 has shown promising preclinical activity across various BRAFV600/RAS-mutant cancer cell lines and human cancer xenografts. "
07/01/2013 - "SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRAS, or KRAS and induces tumor regressions in xenograft models at tolerated doses. "
01/01/2018 - "MK-8353 exhibited comparable potency with SCH772984 across various preclinical cancer models. "

09/22/2021 - "SCH772984 treatment improved survival in the LPS-induced lethal endotoxemia and cecal ligation and puncture (CLP) mouse models of sepsis, and reduced plasma levels of Ccl2/Mcp1. "